BC
NBIX icon

Burney Company’s Neurocrine Biosciences NBIX Stock Holding History

Burney Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
6,201
+880
+17% +$131K 0.03% 345
2026
Q1 		$701K Sell
5,321
-3,369
-39% -$447K 0.02% 386
2025
Q4 		$1.23M Sell
8,690
-20,135
-70% -$2.92M 0.04% 305
2025
Q3 		$4.05M Buy
28,825
+19,302
+203% +$2.62M 0.13% 156
2025
Q2 		$1.2M Sell
9,523
-3,980
-29% -$456K 0.04% 292
2025
Q1 		$1.49M Sell
13,503
-13,849
-51% -$1.75M 0.05% 257
2024
Q4 		$3.73M Sell
27,352
-99,173
-78% -$12.3M 0.13% 158
2024
Q3 		$14.6M Buy
126,525
+43,947
+53% +$6.02M 0.52% 50
2024
Q2 		$11.4M Buy
82,578
+3,236
+4% +$444K 0.43% 62
2024
Q1 		$10.9M Sell
79,342
-8,895
-10% -$1.21M 0.42% 59
2023
Q4 		$11.6M Buy
88,237
+14,990
+20% +$1.73M 0.49% 49
2023
Q3 		$8.24M Buy
73,247
+33,045
+82% +$3.48M 0.39% 67
2023
Q2 		$3.79M Buy
40,202
+20,238
+101% +$1.98M 0.17% 154
2023
Q1 		$2.02M Buy
19,964
+3,332
+20% +$347K 0.1% 221
2022
Q4 		$1.99M Buy
+16,632
New +$1.95M 0.1% 202

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Burney Company's NBIX Position: Q2 2026 in Review

Burney Company increased its Neurocrine Biosciences (NBIX) stake by 17% in Q2 2026, buying an estimated $131K and bringing the position to 6,201 shares worth $1.05M. The position accounts for 0.03% of the portfolio, ranked #345.

Burney Company first reported a position in NBIX in Q4 2022 and has held it in 15 quarters since. The position peaked at $14.6M in Q3 2024. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Burney Company held 6,201 shares of Neurocrine Biosciences worth $1.05M as of Q2 2026.
  • Burney Company bought 880 Neurocrine Biosciences shares in Q2 2026, an estimated $131K.
  • Neurocrine Biosciences made up 0.03% of Burney Company's portfolio in Q2 2026, its #345 holding.
  • Burney Company first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 15 quarters since.
  • Burney Company's Neurocrine Biosciences position peaked at $14.6M in Q3 2024.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Burney Company's 13F filing for Q2 2026, filed 15 Jul 2026.